Amazon Supplements, OTC Drugs Ride Lower Prices To Gains In Market Share

Amazon’s Solimo supplement and Basic Care OTC lines unlikely to expand much, says Jefferies analyst Brian Tanquilut. Still, brands are well positioned against retail private label competitors, as most products are priced lower than similar products by Walgreens and CVS.

Las Vegas - Circa July 2017: Amazon.com Fulfillment Center. Amazon is the Largest Internet-Based Retailer in the United States II

[Amazon.com Inc.] likely has few options remaining for extending its Solimo dietary supplement and Basic Care OTC drug brand lines but both are positioned to gain market share with product prices cut lower in the past six months than the biggest private label and store brand competitors.

“There just aren’t a lot of products left that they could launch in the health care bucket that they don’t offer today” in the Solimo line, said Jefferies Americas market analyst Brian Tanquilut in an interview following his Dec. 27 report on Amazon brands' sales

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Wellness

People On The Move: Appointments At Haleon, Wellnex, Orkla

 
• By 

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.

US Consumer Health Market People News: Niagen, INW, Hims & Hers, NOW, Tranont, More

 

Amazon executive moves Hims & Hers; INW Manufacturing adds IPA board member as CSO; USC Gerontology School dean joins Niagen advisory board; ‘Be You, NOW’ campaign during Women’s Health Month; direct seller Tranont expands advisory board; Vitamin Shoppe, sports nutrition brands support Team Red, White & Blue cross-US runners; and Powerade supports Morgan's Message.

C&D Divesting Flawless, Spinbrush Lines, Says Gummy Vitamin Brands Might Not Stick

 

C&D reports Q1 net sales dropped 2.4% to $1.48bn, below its guidance for around 1% growth. Its brands’ sales at retail and market share grew in the quarter, but “experienced slowing category growth in the US market” as retailers reduced inventory levels.